Soligenix Inc.
$ 0.44
-7.82%
05 Jun - close price
- Market Cap 6,571,600 USD
- Current Price $ 0.44
- High / Low $ 0.48 / 0.41
- Stock P/E N/A
- Book Value 0.29
- EPS -1.45
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.00 %
- ROE -3.27 %
- 52 Week High 6.23
- 52 Week Low 0.28
About
Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$1.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-03 | 2025-12-31 | 2025-11-07 | 2025-08-14 | 2025-05-09 | 2025-03-21 | 2024-11-08 | 2024-08-09 | 2024-05-10 | 2024-03-15 | 2023-11-13 | 2023-08-21 |
| Reported EPS | -0.28 | None | -0.58 | -0.82 | -1.06 | -1.14 | -0.78 | -1.31 | -0.18 | -0.23 | -0.16 | -0.22 |
| Estimated EPS | -0.24 | -0.27 | -0.12 | -0.11 | -0.67 | -1.56 | -1.09 | -1.77 | -0.19 | -0.19 | -0.29 | -0.49 |
| Surprise | -0.04 | 0 | -0.46 | -0.71 | -0.39 | 0.42 | 0.31 | 0.46 | 0.01 | -0.04 | 0.13 | 0.27 |
| Surprise Percentage | -16.6667% | None% | -383.3333% | -645.4545% | -58.209% | 26.9231% | 28.4404% | 25.9887% | 5.2632% | -21.0526% | 44.8276% | 55.102% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNGX
2026-05-29 14:39:42
Soligenix, Inc. filed an 8-K with the SEC announcing an increase in its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by $2,956,000, bringing the total to $6,406,000. This move, approved by the Board of Directors, aims to raise capital but also introduces potential dilution risk for shareholders. The company has authorization for its President, CEO, or CFO to execute the necessary filings and list new shares on the Nasdaq Capital Market, with a pricing committee determining per-share offering prices.
2026-05-28 21:38:57
Soligenix (NASDAQ: SNGX) has increased its at-the-market stock offering capacity by an additional $2.96 million through a prospectus supplement. This expands an existing sales agreement with Rodman & Renshaw LLC, under which the company had previously sold approximately $3.445 million in common stock. The disclosure was made via an 8-K filing, which includes a legal opinion from Duane Morris LLP regarding the legality of the new shares.
2026-05-28 21:38:57
Soligenix, Inc. has updated its at-the-market (ATM) offering capacity to $2.96 million for common stock under a Sales Agreement with Rodman & Renshaw LLC. This adjustment is based on a public float of $24.51 million and aligns with General Instruction I.B.6 of Form S-3. The company previously sold $5.21 million under the same instruction in the past 12 months, and the sale of additional shares is contingent on market activity and potential increases in public float.
2026-05-28 21:38:57
Soligenix (SNGX) has increased the maximum amount of common stock available for sale under its at-market sales agreement by $2,956,000. This follows a prospectus supplement filed on May 28, 2026. The company had previously sold approximately $3,445,000 of common stock under the same agreement.
2026-05-28 05:39:44
An investor, Delmas W, shared a brief post on the Moomoo community platform noting a "small win but consistent so far" with Soligenix (SNGX.US). The post was part of a discussion thread titled "Share Your Profit/Loss." The content itself is very minimal, serving more as a comment than an article.
2026-05-27 17:36:00
Soligenix (SNGX) stock surged over 102% after the company highlighted the potential applicability of its thermostable filovirus vaccine platform to the Bundibugyo virus, associated with a recent Ebola outbreak. The update, detailed in a May 26, 2026 press release, discussed a rapid vaccine development approach utilizing existing work, leading to momentum buying and significant trading volume for the thinly traded micro-cap stock. Despite the stock climb, institutional investors showed a net decrease in holdings in recent quarters.
